Redesigning mRNA Drug Substance Manufacturing: Integrating IVT & Continuous Oligo-dT Purification to Reduce Cost & Improve Quality
- Designing an intergrated end-to-end RNA manufacturing system combining IVT synthesis, purification, formulation and sterile filtration
- Evaluating how integrated purification strategies support continuous and scalable manufacturing without compromising drug substance quality or regulatory robustness
- Lessons from the Innovate UK and CEPI-funded development programs, translating research-stage automation to GMP environments